Hepatitis C - Pipeline Review, H2 2016

Date: September 30, 2016
Pages: 523
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: HE5876B7CC2EN
Leaflet:

Download PDF Leaflet

Hepatitis C - Pipeline Review, H2 2016
Hepatitis C - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis C - Pipeline Review, H2 2016, provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape.

Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting The predisposing factors of hepatitis C include dialysis, organ transplant and blood transfusion. Offspring of an infected mother also has high chances of contracting the disease. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis C - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 33, 19, 1, 56, 41 and 4 respectively for Similarly, the Universities portfolio in Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 2, 1, 9 and 24 molecules, respectively for Hepatitis C.

Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis C (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis C (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis C (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis C (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Hepatitis C Overview
Therapeutics Development
Hepatitis C - Therapeutics under Development by Companies
Hepatitis C - Therapeutics under Investigation by Universities/Institutes
Hepatitis C - Pipeline Products Glance
Hepatitis C - Products under Development by Companies
Hepatitis C - Products under Investigation by Universities/Institutes
Hepatitis C - Companies Involved in Therapeutics Development
Hepatitis C - Therapeutics Assessment
Drug Profiles
Hepatitis C - Dormant Projects
Hepatitis C - Discontinued Products
Hepatitis C - Product Development Milestones
Appendix 501

LIST OF TABLES

Number of Products under Development for Hepatitis C, H2 2016
Number of Products under Development for Hepatitis C - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Hepatitis C - Pipeline by 3-V Biosciences, Inc., H2 2016
Hepatitis C - Pipeline by AbbVie Inc, H2 2016
Hepatitis C - Pipeline by AIMM Therapeutics B.V., H2 2016
Hepatitis C - Pipeline by Akshaya Bio Inc., H2 2016
Hepatitis C - Pipeline by Amarillo Biosciences, Inc., H2 2016
Hepatitis C - Pipeline by Amarna Therapeutics B.V., H2 2016
Hepatitis C - Pipeline by ARA Healthcare Pvt. Ltd., H2 2016
Hepatitis C - Pipeline by Aviragen Therapeutics, Inc., H2 2016
Hepatitis C - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H2 2016
Hepatitis C - Pipeline by Benitec Biopharma Limited, H2 2016
Hepatitis C - Pipeline by Beta Pharma, Inc., H2 2016
Hepatitis C - Pipeline by Biogenomics Limited, H2 2016
Hepatitis C - Pipeline by BioLineRx, Ltd., H2 2016
Hepatitis C - Pipeline by Bionor Pharma ASA, H2 2016
Hepatitis C - Pipeline by Biotest AG, H2 2016
Hepatitis C - Pipeline by Biotron Limited, H2 2016
Hepatitis C - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Hepatitis C - Pipeline by Bolder Biotechnology, Inc., H2 2016
Hepatitis C - Pipeline by Bristol-Myers Squibb Company, H2 2016
Hepatitis C - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016
Hepatitis C - Pipeline by Cocrystal Pharma, Inc., H2 2016
Hepatitis C - Pipeline by Conatus Pharmaceuticals Inc., H2 2016
Hepatitis C - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016
Hepatitis C - Pipeline by DEKK-TEC, Inc., H2 2016
Hepatitis C - Pipeline by Delpor, Inc., H2 2016
Hepatitis C - Pipeline by Digna Biotech, S.L., H2 2016
Hepatitis C - Pipeline by Enanta Pharmaceuticals, Inc., H2 2016
Hepatitis C - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Hepatitis C - Pipeline by Formune S.L., H2 2016
Hepatitis C - Pipeline by Genecode AS, H2 2016
Hepatitis C - Pipeline by GeneCure LLC, H2 2016
Hepatitis C - Pipeline by Gilead Sciences, Inc., H2 2016
Hepatitis C - Pipeline by GinkgoPharma Co. Ltd., H2 2016
Hepatitis C - Pipeline by GlaxoSmithKline Plc, H2 2016
Hepatitis C - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
Hepatitis C - Pipeline by HEC Pharm Co., Ltd., H2 2016
Hepatitis C - Pipeline by ImmunoBiology Limited, H2 2016
Hepatitis C - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
Hepatitis C - Pipeline by Integrated BioTherapeutics, Inc., H2 2016
Hepatitis C - Pipeline by JN-International Medical Corporation, H2 2016
Hepatitis C - Pipeline by Johnson & Johnson, H2 2016
Hepatitis C - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
Hepatitis C - Pipeline by Kineta, Inc., H2 2016
Hepatitis C - Pipeline by LG Life Science LTD., H2 2016
Hepatitis C - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016
Hepatitis C - Pipeline by Medivir AB, H2 2016
Hepatitis C - Pipeline by Merck & Co., Inc., H2 2016
Hepatitis C - Pipeline by Microbio Co., Ltd., H2 2016
Hepatitis C - Pipeline by Microbiotix, Inc., H2 2016
Hepatitis C - Pipeline by MultiCell Technologies, Inc., H2 2016
Hepatitis C - Pipeline by NeuroVive Pharmaceutical AB, H2 2016
Hepatitis C - Pipeline by Novartis AG, H2 2016
Hepatitis C - Pipeline by NovaTarg Therapeutics, Inc, H2 2016
Hepatitis C - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
Hepatitis C - Pipeline by Pfenex Inc., H2 2016
Hepatitis C - Pipeline by Pfizer Inc., H2 2016
Hepatitis C - Pipeline by PharmaEssentia Corporation, H2 2016
Hepatitis C - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016
Hepatitis C - Pipeline by Presidio Pharmaceuticals, Inc., H2 2016
Hepatitis C - Pipeline by Profectus BioSciences, Inc., H2 2016
Hepatitis C - Pipeline by Regulus Therapeutics Inc., H2 2016
Hepatitis C - Pipeline by REPLICor Inc., H2 2016
Hepatitis C - Pipeline by Rodos BioTarget GmbH, H2 2016
Hepatitis C - Pipeline by Savoy Pharmaceuticals, Inc., H2 2016
Hepatitis C - Pipeline by SomaGenics, Inc., H2 2016
Hepatitis C - Pipeline by Sorrento Therapeutics, Inc., H2 2016
Hepatitis C - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2016
Hepatitis C - Pipeline by TaiGen Biotechnology Co., Ltd., H2 2016
Hepatitis C - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H2 2016
Hepatitis C - Pipeline by TGV-Laboratories, H2 2016
Hepatitis C - Pipeline by Therapix Biosciences Ltd., H2 2016
Hepatitis C - Pipeline by Therapure Biopharma Inc., H2 2016
Hepatitis C - Pipeline by Vakzine Projekt Management GmbH, H2 2016
Hepatitis C - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016
Hepatitis C - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2016
Hepatitis C - Pipeline by Zylacta Corporation, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Hepatitis C - Dormant Projects, H2 2016
Hepatitis C - Dormant Projects (Contd..1), H2 2016
Hepatitis C - Dormant Projects (Contd..2), H2 2016
Hepatitis C - Dormant Projects (Contd..3), H2 2016
Hepatitis C - Dormant Projects (Contd..4), H2 2016
Hepatitis C - Dormant Projects (Contd..5), H2 2016
Hepatitis C - Dormant Projects (Contd..6), H2 2016
Hepatitis C - Dormant Projects (Contd..7), H2 2016
Hepatitis C - Dormant Projects (Contd..8), H2 2016
Hepatitis C - Dormant Projects (Contd..9), H2 2016
Hepatitis C - Dormant Projects (Contd..10), H2 2016
Hepatitis C - Dormant Projects (Contd..11), H2 2016
Hepatitis C - Dormant Projects (Contd..12), H2 2016
Hepatitis C - Dormant Projects (Contd..13), H2 2016
Hepatitis C - Dormant Projects (Contd..14), H2 2016
Hepatitis C - Dormant Projects (Contd..15), H2 2016
Hepatitis C - Dormant Projects (Contd..16), H2 2016
Hepatitis C - Dormant Projects (Contd..17), H2 2016
Hepatitis C - Dormant Projects (Contd..18), H2 2016
Hepatitis C - Dormant Projects (Contd..19), H2 2016
Hepatitis C - Dormant Projects (Contd..20), H2 2016
Hepatitis C - Dormant Projects (Contd..21), H2 2016
Hepatitis C - Dormant Projects (Contd..22), H2 2016
Hepatitis C - Dormant Projects (Contd..23), H2 2016
Hepatitis C - Dormant Projects (Contd..24), H2 2016
Hepatitis C - Dormant Projects (Contd..25), H2 2016
Hepatitis C - Dormant Projects (Contd..26), H2 2016
Hepatitis C - Dormant Projects (Contd..27), H2 2016
Hepatitis C - Discontinued Products, H2 2016
Hepatitis C - Discontinued Products (Contd..1), H2 2016
Hepatitis C - Discontinued Products (Contd..2), H2 2016
Hepatitis C - Discontinued Products (Contd..3), H2 2016
Hepatitis C - Discontinued Products (Contd..4), H2 2016
Hepatitis C - Discontinued Products (Contd..5), H2 2016
Hepatitis C - Discontinued Products (Contd..6), H2 2016
Hepatitis C - Discontinued Products (Contd..7), H2 2016 510

LIST OF FIGURES

Number of Products under Development for Hepatitis C, H2 2016
Number of Products under Development for Hepatitis C - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Hepatic Encephalopathy - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 64 pages
Hepatitis B - Pipeline Review, H2 2015 US$ 1,700.00 Nov, 2015 · 385 pages

Ask Your Question

Hepatitis C - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: